

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/02	A1	(11) International Publication Number: WO 94/28922 (43) International Publication Date: 22 December 1994 (22.12.94)
(21) International Application Number: PCT/US94/06397 (22) International Filing Date: 7 June 1994 (07.06.94) (30) Priority Data: 08/075,048 10 June 1993 (10.06.93) US (71) Applicant: ALLERGAN, INC. [US/US]; 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US). (72) Inventors: AOKI, K., Roger, 25472 Earhart Road, Laguna Hills, CA 92653 (US). GRAYSTON, Michael, W.; 12 Mandarin, Irvine, CA 92714 (US). CARLSON, Steven, R.; 29991 Happy Sparrow Lane, Laguna Niguel, CA 92677 (US). LEON, Judith, M.; 29992 Running Deer Lane, Laguna Niguel, CA 92677 (US). (74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, P.O. Box 19534, Irvine, CA 92713-9534 (US).	(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: **TREATMENT OF NEUROMUSCULAR DISORDERS AND CONDITIONS WITH DIFFERENT BOTULINUM SEROTYPE**

(57) Abstract

A method of treating a patient suffering from a disease, disorder or condition includes the administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient a therapeutically effective amount of another botulinum toxin of a different serotype.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

TREATMENT OF NEUROMUSCULAR DISORDERS AND CONDITIONS
WITH DIFFERENT BOTULINUM SEROTYPE

5 FIELD OF THE INVENTION

 The present invention provides novel methods for
treating diseases of the nervous system, e.g.,
neuromuscular disorders and conditions, with botulinum
10 toxins. In addition, the present invention provides
methods useful in all tissue and organ systems which
involve the release of neurotransmitters, especially
acetylcholine. These cholinergic transmission systems
include neuromuscular junctions (muscles), smooth
15 muscles (gut, sphincters, etc.) and secretions
(salivation and mucus).

BACKGROUND OF THE INVENTION

20 A bacterial toxin, botulinum toxin, in particular
botulinum toxin type A, has been used in the treatment
of a number of neuromuscular disorders and conditions
involving muscular spasm; for example, strabismus,
blepharospasm, spasmodic torticollis (cervical
25 dystonia), oromandibular dystonia and spasmodic
dysphonia (laryngeal dystonia). The toxin binds
rapidly and strongly to presynaptic cholinergic nerve
terminals and inhibits the exocytosis of acetylcholine
by decreasing the frequency of acetylcholine release.
30 This results in local paralysis and hence relaxation
of the muscle afflicted by spasm.

 For one example of treating neuromuscular
disorders, see U.S. Patent No. 5,053,005 to Borodic,
35 which suggests treating curvature of the juvenile

-2-

spine, i.e., scoliosis, with an acetylcholine release inhibitor, preferably botulinum toxin A.

5 For the treatment of strabismus with botulinum toxin type A, see Elston, J.S., et al., *British Journal of Ophthalmology*, 1985, 69, 718-724 and 891-896. For the treatment of blepharospasm with botulinum toxin type A, see Adenis, J.P., et al., *J. Fr. Ophthalmol.*, 1990, 13 (5) at pages 259-264. For
10 treating squint, see Elston, J.S., *Eye*, 1990, 4(4):VII. For treating spasmodic and oromandibular dystonia torticollis, see Jankovic et al., *Neurology*, 1987, 37, 616-623.

15 Spasmodic dysphonia has been treated with botulinum toxin type A. See Blitzner et al., *Ann. Otol. Rhino. Laryngol.*, 1985, 94, 591-594. Lingual dystonia was treated with botulinum toxin type A according to Brin et al., *Adv. Neurol.* (1987) 50, 599-
20 608. Finally, Cohen et al., *Neurology* (1987) 37 (Suppl. 1), 123-4, discloses the treatment of writer's cramp with botulinum toxin type A.

25 The term botulinum toxin is a generic term embracing the family of toxins produced by the anaerobic bacterium *Clostridium botulinum* and, to date, seven immunologically distinct neurotoxins serotype have been identified. These have been given the designations A, B, C, D, E, F and G. For further
30 information concerning the properties of the various botulinum toxins, reference is made to the article by Jankovic and Brin, *The New England Journal of Medicine*, No. 17, 1990, pp. 1186-1194, and to the review by Charles L. Hatheway in Chapter 1 of the book
35 entitled *Botulinum Neurotoxin and Tetanus Toxin*, L. L.

Simpson, Ed., published by Academic Press Inc. of San Diego, California, 1989, the disclosures in which are incorporated herein by reference.

5 The neurotoxic component of botulinum toxin has
a molecular weight of about 150 kilodaltons and is
thought to comprise a short polypeptide chain of about
10 50 kD which is considered to be responsible for the
toxic properties of the toxin, i.e., by interfering
with the exocytosis of acetylcholine, by decreasing
the frequency of acetylcholine release, and a larger
polypeptide chain of about 100 kD which is believed to
be necessary to enable the toxin to bind to the pre-
synaptic membrane. The "short" and "long" chains are
15 linked together by means of a simple disulfid bridge.
(It is noted that certain serotype of botulinum toxin,
e.g., type E, may exist in the form of a single chain
un-nicked protein, as opposed to a dichain. The
single chain form is less active but may be converted
20 to the corresponding dichain by nicking with a
protease, e.g., trypsin. Both the single and the
dichain are useful in the method of the present
invention.)

25 Immunotoxin conjugates of ricin and antibodies,
which are characterized as having enhanced cytotoxi-
city through improving cell surface affinity, are
disclosed in European Patent Specification 0 129 434.
The inventors note that botulinum may be utilized in
30 place of ricin.

Botulinum toxin is obtained commercially by
establishing and growing cultures of *C. botulinum* in
a fermenter and then harvesting and purifying the
35 fermented mixture in accordance with known techniques.

-4-

Botulinum toxin type A, the toxin type generally utilized in treating neuromuscular conditions, is currently available commercially from several sources; for example, from Port Products Ltd. UK, under the trade name "DYSPORT," and from Allergan, Inc., Irvine, California, under the trade name BOTOX®.

It has been found, however, that some patients experience a loss of clinical responsiveness to botulinum toxin injections. One explanation for this action is that the patient has developed neutralizing antibodies or an immune response to, for example, botulinum toxin type A. Alternatively, the type of immune response may be different from just neutralizing antibodies. These include: (1) Allergic reaction where there is immediate local swelling, redness and itching. This may also be associated with general flu-like symptoms. (2) A delayed-type hypersensitivity manifested as swelling and redness at the injection site 48 to 72 hours after injection. (3) Or, a serum sickness-like response where the patient experiences flu-like symptoms. All of these immune-based reactions to type A dictate alternate serotype therapy to maintain clinical benefits.

A further hypothesis may explain loss of clinical responsiveness to botulinum toxin injections. This does not include interaction of other medications which may interfere with the action of botulinum toxin (i.e., angiotensin converting enzyme inhibitor class of antihypertensives and other endopeptidase inhibitors, aminopyridines, acetylcholine esterase inhibitors, etc.). One possible explanation for the loss of responsiveness is an alteration in the neuronal binding of toxin to the presynaptic

-5-

cholinergic nerve terminal. An alternation of gangliocides could reduce the binding efficacy of the toxin and thus reduce the amount of toxin internalized. Alternatively, an induction of proteases may cause an enhanced breakdown of the toxin either in the extracellular milieu or within the neuron. Finally, the neuron may change the amino acid composition of the target protein for the light chain of the toxin to reduce or eliminate its effect on the exocytotic mechanism.

It is one object of the invention to provide novel treatments of neuromuscular disorders and conditions with botulinum toxin type A followed with treatments of botulinum toxin types B, C, D, E, F and G.

SUMMARY OF THE INVENTION

The present invention provides a method of treating a neuromuscular disorder or condition such as strabismus and other disorders of ocular motility, e.g., comitant and vertical strabismus, lateral rectus palsy, nystagmus, dysthyroid myopathy, etc.; dystonia, e.g., focal dystonias such as spasmodic torticollis, writer's cramp, blepharospasm, oromandibular dystonia and the symptoms thereof, e.g., bruxism, Wilson's disease, tardive dystonia, laryngeal dystonia etc.; other dystonias, e.g., tremor, tics, segmental myoclonus; spasms, such as spasticity due to chronic multiple sclerosis, spasticity resulting in abnormal bladder control, e.g., in patients with spinal cord injury, animus, back spasm, charley horse etc.; tension headaches; levator pelvic syndrome; spina bifida, tardive dyskinesia; Parkinson's and limb (focal) dystonia and stuttering, etc. of a patient,

-6-

which method comprises administering to the patient suffering from said disorder or condition a therapeutically effective amount of a botulinum A followed with a neurotoxin of a different serotype, i.e., one
5 selected from the group consisting of botulinum toxin types B, C, D, E, F and G.

10 The clinical features of the above-listed neuromuscular disorders and conditions are described in Jankovic and Brin, cited above, and in Quinn, *Disorders of Movement*, Academic Press, 1989, all of which are incorporated herein by reference.

15 The present invention further provides compositions of said botulinum toxins in a vehicle suitable for injection of said toxins into the appropriate region of the patient to be treated. Alterations of the vehicle and excipient may include
20 materials designed to retain the injected toxin in the local area.

The present invention further provides a method for treating neuromuscular disorders or conditions in
25 which the patient experiences a loss of clinical response to an initial treatment of botulinum toxin.

More specifically, a method in accordance with the present invention includes administering to the
30 patient a therapeutically effective amount of botulinum toxin of a different serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient another botulinum toxin

-7-

of the selected serotype, said another botulinum toxin being administered in therapeutically effect amounts.

5 More particularly, the method in accordance with the present invention includes initial treatment with botulinum toxin type A followed by treatment with another botulinum toxin selected from the group consisting of types B, C, D, E and F.

10 Alternatively, the initial treatment may be with botulinum toxin type B followed by another botulinum toxin serotype selected from the group consisting of types A, C, D, E and F.

15 An alternative embodiment of the present invention includes the administration to a patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient develops neutralizing antibodies and thereafter administration
20 to the patient of another botulinum toxin of a different serotype, said another botulinum toxin being administered in a therapeutically effective amount.

DETAILED DESCRIPTION

25 The botulinum toxins used according to the present invention are botulinum toxin serotype A, B, C, D, E, F and G.

30 Each serotype of botulinum toxin has been identified as immunologically different proteins through the use of specific antibodies. For example, if the antibody (antitoxin) recognizes, that is, neutralizes the biological activity of, for example,
35 type A it will not recognize types B, C, D, E, F or G.

While all of the botulinum toxins appear to be zinc endopeptidases, the mechanism of action of different serotypes, for example, A and E within the neuron appear to be different than that of type B. In addition, the neuronal surface "receptor" for the toxin appears to be different for the serotypes.

The physiologic groups of *Clostridium botulinum* types are listed in Table I.

Table I. Physiologic Groups of *Clostridium botulinum*

Group	Toxin Sero-Type	Biochemistry	Milk Digest	Glucose Fermentation	Lipase	Phages & Plasmids	Phenotypically Related <i>Clostridium</i> (nontoxicogenic)
I	A,B,F	proteolytic saccharolytic	+	+	+	+	<i>C. sporogenes</i>
II	B,E,F	nonproteolytic saccharolytic psychotrophic	-	+	+	+	
III	C,D	nonproteolytic saccharolytic	+	+	+	+	<i>C. novyi</i>
IV	G	proteolytic nonsaccharolytic	+	-	-	-	<i>C. subterminale</i>

These toxin types may be produced by selection from the appropriate physiologic group of *Clostridium botulinum* organisms. the organisms designated as Group I are usually referred to as proteolytic and produce botulinum toxins of types A, B and F. The organisms designated as Group II are saccharolytic and produce botulinum toxins of types B, E and F. The organisms designated as Group III produce only botulinum toxin types C and D and are distinguished from organisms of Groups I and II by the production of significant amounts of propionic acid. Group IV organisms only produce neurotoxin of type G.

The production of any and all of the botulinum toxin types A, B, C, D, E, F and G are described in

-9-

Chapter 1 of *Botulinum Neurotoxin and Tetanus Toxin*, cited above, and/or the references cited therein. Botulinum toxins types B, C, D, E, F and G are also available from various species of clostridia. Currently fourteen species of clostridia are considered pathogenic.

Most of the pathogenic strains produce toxins which are responsible for the various pathological signs and symptoms. Organisms which produce botulinum toxins have been isolated from botulism outbreaks in humans (types A, B, E and F) and animals (types C and D). Their identities were described through the use of specific antitoxins (antibodies) developed against the earlier toxins. Type G toxin was found in soil and has low toxigenicity. However, it has been isolated from autopsy specimens, but thus far there has not been adequate evidence that type G botulism has occurred in humans.

In general, four physiologic groups of *C. botulinum* are recognized (I, II, III, IV). The organisms capable of producing a serologically distinct toxin may come from more than one physiological group. For example, Type B and F toxins can be produced by strains from Group I or II. In addition, other strains of clostridial species (*C. baratii*, type F; *C. butyricum*, type E; *C. novyi*, type C₁ or D) have been identified which can produce botulinum neurotoxins.

Preferably, the toxin is administered by means of intramuscular injection directly into a spastic muscle, in the region of the neuromuscular junction, although alternative types of administration (e.g.,

-10-

subcutaneous injection), which can deliver the toxin directly to the affected muscle region, may be employed where appropriate. The toxin can be presented as a sterile pyrogen-free aqueous solution or dispersion and as a sterile powder for reconstitution into a sterile solution or dispersion.

Where desired, tonicity adjusting agents such as sodium chloride, glycerol and various sugars can be added. Stabilizers such as human serum albumin may also be included. The formulation may be preserved by means of a suitable pharmaceutically acceptable preservative such as a paraben, although preferably it is unpreserved.

It is preferred that the toxin is formulated in unit dosage form; for example, it can be provided as a sterile solution in a vial or as a vial or sachet containing a lyophilized powder for reconstituting a suitable vehicle such as water for injection.

In one embodiment, the botulinum toxin is formulated in a solution containing saline and pasteurized human serum albumin, which stabilizes the toxin and minimizes loss through non-specific adsorption. The solution is sterile filtered (0.2 micron filter), filled into individual vials and then vacuum-dried to give a sterile lyophilized powder. In use, the powder can be reconstituted by the addition of sterile unpreserved normal saline (sodium chloride 0.9% for injection).

The dose of toxin administered to the patient will depend upon the severity of the condition; e.g., the number of muscle groups requiring treatment, the

-11-

age and size of the patient and the potency of the toxin. The potency of the toxin is expressed as a multiple of the LD₅₀ value for the mouse, one unit (U) of toxin being defined as being the equivalent amount
5 of toxin that kills 50% of a group of 18 to 20 female Swiss-Webster mice, weighing 20 grams each.

The dosages used in human therapeutic applications are roughly proportional to the mass of
10 muscle being injected. Typically, the dose administered to the patient may be up to about 1,000 units; for example, up to about 500 units, and preferably in the range from about 80 to about 460 units per patient per treatment, although smaller or larger doses may be
15 administered in appropriate circumstances.

As the physicians become more familiar with the use of this product, the dose may be changed. In the botulinum toxin type A, available from Porton,
20 DYSPORT, 1 nanogram (ng) contains 40 U. 1 ng of the botulinum toxin type A, available from Allergan, Inc., i.e., BOTOX®, contains 4 U. The potency of botulinum toxin and its long duration of action mean that doses will tend to be administered on an infrequent basis.

25

Ultimately, however, both the quantity of toxin administered and the frequency of its administration will be at the discretion of the physician responsible
30 for the treatment and will be commensurate with questions of safety and the effects produced by the toxin.

The invention will now be illustrated by
35 reference to the following nonlimiting examples.

-12-

In each of the examples, the appropriate muscles of each patient are injected with sterile solutions containing the botulinum toxins. Total patient doses range from 80 U to 460 U. Before injecting any muscle group, careful consideration is given to the anatomy of the muscle group, the aim being to inject the area with the highest concentration of neuromuscular junctions, if known. Before injecting the muscle, the position of the needle in the muscle is confirmed by putting the muscle through its range of motion and observing the resultant motion of the needle end. General anaesthesia, local anaesthesia and sedation are used according to the age of the patient, the number of sites to be injected, and the particular needs of the patient. In accordance with the present invention, multiple injections are necessary to achieve the desired result, due to the patient's experiencing loss of clinical response to an initial treatment. Also, some injections, depending on the muscle to be injected, may require the use of fine, hollow, teflon-coated needles, guided by electromyography.

Following injection, it is noted that there are no systemic or local side effects and none of the patients are found to develop extensive local hypotonicity. The majority of patients show an improvement in function both subjectively and when measured objectively.

-13-

Example 1The Use of Botulinum Toxin Serotype A, B and F
in the Treatment of Tardive Dyskinesia

5 A patient, suffering from tardive dyskinesia
resulting from the treatment with an antipsychotic
drug, such as haloperidol, is treated with an
effective amount of botulinum toxin type A by direct
10 injection of such toxin into the muscles identified by
the physician. After two to four days, the symptoms
of tardive dyskinesia, i.e., orofacial dyskinesia,
athetosis, dystonia, chorea, tics and facial
grimacing, etc., are markedly reduced. Upon continued
administration of the botulinum toxin type A, a loss
15 of clinical response is noted. Thereafter, an
effective amount of botulinum toxin type B is injected
and the symptoms of tardive dyskinesia continue to be
markedly reduced.

20 Example 1(a)

 The method of Example 1 is repeated, except that
a patient suffering from tardive dyskinesia is
injected with an effective amount of botulinum toxin
25 type A, followed by injection of an effective amount
of botulinum toxin type C. Similar results are
obtained.

30 Example 1(b)

 The method of Example 1 is repeated, except that
a patient suffering from tardive dyskinesia is
injected with an effective amount of botulinum toxin
35 type A, followed by injection of an effective amount

-14-

of botulinum toxin type D. Similar results are obtained.

5

Example 1(c)

The method of Example 1 is repeated, except that a patient suffering from tardive dyskinesia is injected with an effective amount of botulinum toxin type A, followed by injection of an effective amount of botulinum toxin type E. Similar results are obtained.

10

Example 1(d)

15

The method of Example 1 is repeated, except that a patient suffering from tardive dyskinesia is injected with an effective amount of botulinum toxin type A, followed by injection of an effective amount of botulinum toxin type F. Similar results are obtained.

20

Example 2Use of Botulinum Toxin in the Treatment
of Spasmodic Torticollis

25

A male, suffering from spasmodic torticollis, as manifested by spasmodic or tonic contractions of the neck musculature, producing stereotyped abnormal deviations of the head, the chin being rotated to one side, and the shoulder being elevated toward the side at which the head is rotated, is treated by injection with up to about 300 units, or more, of botulinum toxin type E, (having an activity of one to four days) in the dystonic neck muscles. After the symptoms are substantially alleviated and the patient is able to

30

35

-15-

hold his head and shoulder in a normal position, the patient develops antibodies. Thereafter the patient is injected with botulinum toxin type B and the symptoms continue to be substantially alleviated.

5

Although there has been hereinabove described a use of botulinum toxin serotype for treating neuromuscular disorders and conditions in accordance with the present invention, for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto since many obvious modifications can be made, and it is intended to include within this invention any such modifications as will fall within the scope of the appended claims. Accordingly, any and all modifications, variations, or equivalent arrangements which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.

10

15

20

WHAT IS CLAIMED IS:

1. A method of treating a patient suffering from a neuromuscular disorder or condition, said method comprising administering to the patient a therapeutically effective amount of botulinum toxin of a selected serotype until the patient experiences loss of clinical response to the administered botulinum toxin and thereafter administering to the patient another botulinum toxin of a different serotype, said another botulinum toxin being administered in therapeutically effective amounts.
2. The method according to claim 1 wherein the botulinum toxin is type A and said another botulinum toxin is selected from the group consisting of types B, C, D and F.
3. The method according to claim 1 wherein the botulinum toxin is type E and said another botulinum toxin is selected from the group consisting of types A, B, C, D and F.
4. A method of treating a patient suffering from a neuromuscular disorder or condition, said method comprising administration to the patient of a therapeutically effective amount of botulinum toxin of a selected serotype until the patient develops neutralizing antibodies and thereafter administering to the patient another botulinum toxin of a different serotype, said another botulinum toxin being administered in a therapeutically effective amount.
5. The method according to claim 4 wherein the botulinum toxin is type A and said another botulinum

toxin is selected from the group consisting of types B, C, D, E and F.

6. The method according to claim 4 wherein the botulinum toxin is type B and said another botulinum toxin is selected from the group consisting of types A, C, D, E and F.

5 7. A method of treating a patient suffering from a neuromuscular disorder or condition, said method comprising administering to the patient a therapeutically effective amount of botulinum toxin serotype A until the patient develops neutralizing antibodies and thereafter administering to the patient a therapeutically effective amount of a different serotype of botulinum toxin.

8. The method according to claim 7 wherein the different serotype comprise botulinum toxin types B, C, D, E and F.

5 9. A method of treating a patient suffering from a neuromuscular disorder or condition, said method comprising administering to the patient a therapeutically effective amount of botulinum toxin type B until the patient develops neutralizing antibodies and thereafter administering to the patient a therapeutically effective amount of a serotype different from botulinum toxin type B.

10. The method according to claim 9 wherein the different serotype comprise botulinum toxin types A, C, D, E and F.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/06397

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 05800 (ALLERGAN) 1 April 1993 see the whole document , specially page 12, par. 4	1-10
X	MICROBIOLOGICAL REVIEW, vol.56, no.1, March 1992, WASHINGTON pages 80 - 99 SCHANTZ ET AL. 'Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine' see the whole document, specially page 93, right column	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

5 October 1994

Date of mailing of the international search report

2 1. 10. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/06397

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF NEUROLOGY, vol.239, no.1, January 1992, BERLIN pages 16 - 20 HAMBLETON P. 'Clostridium botulinums toxins : a general review ...' see the whole document ---	1-10
A	THE NEW ENGLAND JOURNAL OF MEDICINE, vol.324, no.17, 25 April 1991, BOSTON pages 1186 - 1194 JANKOVIC J. ET AL. 'Therapeutic Uses of Botulinum Toxin' cited in the application see the whole document ---	1-10
P,X	WO,A,94 00481 (ASSOCIATED SYNAPSE BIOLOGICS) 6 January 1994 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/06397

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/06397

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9305800	01-04-93	AU-A- 2566492	27-04-93
		CA-A- 2119562	01-04-93
		EP-A- 0605501	13-07-94
WO-A-9400481	06-01-94	AU-B- 4646393	24-01-94

Form PCT/ISA/210 (patent family annex) (July 1992)